Agoracom Blog Home

Posts Tagged ‘bot’

VIDEO – Datametrex Reports $10.4m In Net Earnings On $29.5M In Revenue For H1-2021

Posted by AGORACOM-JC at 10:56 AM on Monday, August 16th, 2021
This image has an empty alt attribute; its file name is DM-square.jpg

When it comes to small-cap companies, tech-focused Datametrex AI (DM: TSXV) (D4G: FSE) (DTMXF: OTCQB) is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.

In our newest interview with Datametrex, we sit down with CEO Marshall Gunter to discuss the company’s explosive H1-2021.  

Financial Highlights include:  

  • Revenue of $29,494,191 compared to revenue of $2,763,796 (same period 2020)
  • Net earnings of $10,410,485 compared to ($1,590,239).
  • EBITDA of $12,250,211 compared to ($1,197,679).
  • Cash balance significantly increased to $10,555,375 from $1,971,987 end of 2020.

And if that’s not enough… the company recently announced that passing 2nd round of scrutiny on a $40 Million AI bid.

This interview is a MUST WATCH. Sit back, relax and watch below.

VIDEO – Datametrex $DM.ca $DTMXF CEO Talks Record-Breaking Q1 2021, AI Business, & More $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 12:08 PM on Monday, May 31st, 2021
This image has an empty alt attribute; its file name is DM-square.jpg

When it comes to small-cap companies, tech-focused Datametrex AI is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.

In our newest interview with Datametrex, we sit down with CEO Marshall Gunter to discuss the company’s record-breaking Q1 2021, their explosive AI business, their incredibly successful foray into the COVID-19 market, and more. 

  • Record Q1 Revenue of $19.04 Million up 2,253%
  • Record Adjusted EBITDA of $10.68 Million up 1,548%
  • Net Earnings of 9,560,351 up 1,425%

Check out the interview down below.\

VIDEO – Datametrex $DM.ca $DTMXF CEO Talks Record-Breaking FY2020 with $12.3M In Revenue, Covid-19 Test Kits and More $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 7:12 PM on Friday, April 30th, 2021

When it comes to small-cap companies, tech-focused Datametrex AI is in rarefied air; they have not one but two successful independent divisions each capable of being a company maker: COVID-19 test kit distribution, and AI-driven social media monitoring and discovery.

Financial Highlights for year ending December 31, 2020:

  • Revenue of $12.3M vs. $3.4M for FY 2019
  • An increase of 264%

We sat down with CEO Marshall Gunter to discuss these highlights, the COVID-19 landscape, telemedicine, 2021 plans, and more.

Check out the interview down below.

Datametrex $DM.ca $DTMXF Announces Letter of Intent of Telemedicine Company $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 1:34 PM on Tuesday, March 23rd, 2021
This image has an empty alt attribute; its file name is 72321fd3-ab1d-40a2-af37-397a2993ccb4.png
  • Company to acquire 100% of the issued and outstanding share capital of a telemedicine company that is a subscription service that connects patients with providers or doctors in real-time.
  • Datametrex intends to integrate the Target’s platform into the Company’s core AI technology.

Toronto, Ontario–(Newsfile Corp. – March 23, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that it has entered into a Letter of Intent (the “LOI“) on March 22, 2021, to acquire 100% of the issued and outstanding share capital of a telemedicine company (the “Target”), an arm’s length privately held company, incorporated under the laws of the Province of British Columbia.

Pursuant to its confidentiality obligations, the identity of the Target is confidential and will be subsequently disclosed if the parties enter into a Definitive Agreement (as defined below).

Subject to the completion of satisfactory mutual due diligence within thirty (30) days from the date of the LOI by Datametrex and Target, respectively, pursuant to the terms and conditions of the LOI, Datametrex and the Target will enter into a Definitive Agreement (“Definitive Agreement”).

“The impact of the acquisition of this telemedicine AI business cannot be minimized. The demand for telemedicine continues to be a large area of growth particularly with the current pandemic. We believe that adding this telemedicine element to our existing AI business will drive significant value for our stakeholders,” said Marshall Gunter, Datametrex’s Chief Executive Officer.

The Target is a telemedicine company that is a subscription service that connects patients with providers or doctors in real time. Datametrex intends to integrate the Target’s platform into the Company’s core AI technology.

The Transaction

It is anticipated that the Transaction will be structured as a share acquisition. Datametrex will acquire all of the securities of Target. It is anticipated that the Definitive Agreement will be signed on or before April 15, 2021 or such other date as mutually agreed to by the parties.

Closing of the Transaction is subject to a number of conditions, including but not limited to the following:

  • The Corporation will acquire the Target Shares for an aggregate purchase price of CAD $12 million (the “Purchase Price”). The Purchase Price shall be satisfied through the issuance of an aggregate of 60 million units (the “Consideration Units”). Each Consideration Unit shall comprise one common share in the capital of the Company (a “Consideration Share”) and a common share purchase warrant (a “Consideration Warrant”) in the capital of the Corporation with an exercise price of $0.20 per Consideration Unit; and
  • Each Consideration Unit shall entitle the holder thereof to acquire one common share in the capital of the Corporation at an exercise price of $0.25 per share for a period of 24 months from date of issuance;
  • Issuance of the Consideration Units and its underlying securities shall be subject to the receipt of regulatory approvals including, without limitation, the approval of the TSX Venture Exchange (“TSXV“) and other conditions and will be subject to statutory hold periods under applicable securities legislation;
  • The Board of Directors and shareholders of Target approving the Definitive Agreement and the transfer of the Target shares to the Company in exchange for the payment of the Purchase Price; and
  • The Company and the Target completing and being satisfied with the results of its due diIigence investigations; and
  • The Transaction closing on or before April 15, 2021.

On closing of the Transaction:

  • Target will become a wholly owned subsidiary of the Company.

Datametrex will not assume any debt of the Target and the proposed acquisition of Target is not expected to constitute a fundamental change or result in a change of business for the Company, nor is it expected to result in a change of control of the Company within the meaning of applicable securities laws and the policies of the TSXV.

To read more, click here.

AGORACOM Small Cap 60: Datametrex $DM.ca $DTMXF Social Media Discovery – Fighting Fake News and Disinformation – Fighting #Covid19 $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 1:15 PM on Monday, March 22nd, 2021

VIDEO – Datametrex AI $DM.ca $DTMXF Discusses Company’s M&A Growth Plans For Artificial Intelligence Division $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 5:46 PM on Monday, March 15th, 2021

Datametrex AI Limited has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker.  

The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.

The company announced that it has entered into an LOI to acquire 100% of Perspectum Drone Inspection Services Ltd. an arm’s length privately held artificial intelligence drone imaging predictive analytic services company.

Perspectum is a drone based imaging predictive analytics artificial intelligence (AI) services company, currently focusing on environmental and safety predictive analysis. Datametrex intends to expand the Perspectum platform into the Company’s core Cybersecurity business by integrating the Company’s AI with Perspectum.

“The impact of the acquisition of this AI business cannot be minimized. The demand for imaging predictive analytic reporting continues to be a large area of growth. As businesses and countries continue to work towards zero emissions and carbon neutral footprints, we believe that adding this imaging predictive AI element to our existing cybersecurity business will drive significant value for our stakeholders.”, said Marshall Gunter, Datametrex’s Chief Executive Officer.

As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution.  Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  

Sit back, relax and watch this powerful interview with Datametrex CEO Marshall Gunter.

Datametrex $DM.ca $DTMXF Announces Acquisition of an Imaging Predictive AI Company $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 11:16 AM on Wednesday, March 10th, 2021

Datametrex Announces Acquisition of an Imaging Predictive AI Company

  • Datametrex to buy drone-based AI inspection services company for $3MM
  • “The impact of the acquisition of this AI business cannot be minimized. The demand for imaging predictive analytic reporting continues to be a large area of growth,” said CEO Marshall Gunter.

Toronto, Ontario–(Newsfile Corp. – March 10, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that it has entered into a Letter of Intent (the “LOI“) to acquire 100% of Perspectum Drone Inspection Services Ltd. (“Perspectum”), an arm’s length privately held artificial intelligence drone imaging predictive analytic services company, incorporated under the laws of Alberta.

Subject to the completion of satisfactory mutual due diligence within thirty (30) days by Datametrex and Perspectum, under the terms and conditions of the LOI, Datametrex and Perspectum will enter into a Definitive Agreement (“Definitive Agreement”), pursuant to which Datametrex will acquire 100% of the issued and outstanding shares (“Transaction“) of Perspectum.

“The impact of the acquisition of this AI business cannot be minimized. The demand for imaging predictive analytic reporting continues to be a large area of growth. As businesses and countries continue to work towards zero emissions and carbon neutral footprints, we believe that adding this imaging predictive AI element to our existing cybersecurity business will drive significant value for our stakeholders.”, said Marshall Gunter, Datametrex’s Chief Executive Officer.

Perspectum is a drone based imaging predictive analytics artificial intelligence (AI) services company, currently focusing on environmental and safety predictive analysis. Datametrex intends to expand the Perspectum platform into the Company’s core Cybersecurity business by integrating the Company’s AI with Perspectum.

The Transaction

It is anticipated that the Transaction will be structured as a share acquisition. Datametrex will acquire all of the securities of Perspectum. It is anticipated that the Definitive Agreement will be signed on or before March 31, 2021.

Closing of the Transaction is subject to a number of conditions, including but not limited to the following:

  • The Company will acquire all shares of Perspectum for an aggregate purchase price of CAD $3 million (“Purchase Price”) to be satisfied through the issuance of common shares (“Consideration Shares”) of Datametrex. The number of Consideration Shares to be issued shall be determined based on the Volume Weighted Average Price (“VWAP”) of the common shares of the Company on the facilities of the TSX Venture Exchange for the thirty days prior to the closing date.
  • The Company will place a number of shares equivalent in value to $500,000 in escrow (“Escrow Shares”). The Escrow Shares held in escrow will automatically be released when Perspectum achieves gross revenue of $600,000 following the closing of the Transaction. Should Perspectum not achieve $600,000 of gross revenue in the 16 month period following the Transaction, the Escrow Shares will be cancelled.
  • Issuance of the Consideration Shares shall be subject to the receipt of regulatory approvals including, without limitation, the approval of the TSX Venture Exchange (“TSXV“) and other conditions and will be subject to statutory hold periods.
  • Datametrex will pay a 5% finders’ fee in connection with the Transaction.
  • The Board of Directors and shareholders of Perspectum approving the Definitive Agreement and the transfer of the Perspectum shares to the Company in exchange for the payment of the Purchase Price.
  • The Company completing and being satisfied with the results of its due diIigence investigations.
  • The Transaction to be completed by April 30, 2021.

On closing of the Transaction,

  • Perspectum will become a wholly owned subsidiary of the Company.
  • Ty Pfeifer shall be appointed President of the subsidiary.
  • The Company shall fund the subsidiary with $550,000 to allow the subsidiary to complete its AI intergration and purchase a second drone/camera platform.

To read more, click here.

Datametrex $DM.ca Secures COVID-19 Antigen Detection Kits

Posted by AGORACOM-JC at 9:10 AM on Wednesday, August 12th, 2020

  • Announced that it has secured rights to sell and distribute South Korean manufacturer PCL, Inc.’s (“PCL”) COV05 COVID19 Rapid Antigen Detection Kits
  • These test kits are suitable for point of care tests. No extra equipment is needed. They are easy to use with over 97% accuracy, and results are available in 5 to 10 minutes
  • Antigen Rapid Diagnosis Kit developed by PCL is a method of fluorescently measuring the presence of a COVID-19 infection

TORONTO, Aug. 12, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has secured rights to sell and distribute South Korean manufacturer PCL, Inc.’s (“PCL”) COV05 COVID19 Rapid Antigen Detection Kits. These test kits are suitable for point of care tests. No extra equipment is needed. They are easy to use with over 97% accuracy, and results are available in 5 to 10 minutes.

The Antigen Rapid Diagnosis Kit developed by PCL is a method of fluorescently measuring the presence of a COVID-19 infection. It is an in-vitro diagnostic medicaldevice to detect the SARS-CoV-2 antigen from a person’s oropharyngeal and nasopharyngeal secretions if the specimen contains antigens to SARS-CoV-2, a colored line appears in the T line area.

View the PCL test by clicking the link PCL COVID-19 ANTIBODY TEST – COV0

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy,” said Marshall Gunter, CEO of Datametrex. “These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

PCL states that the clinical sensitivity (confirmed the actual positive of the approved person) is 100% and the clinical specificity (confirmed the actual negative of the negative person) is 97.78%. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

The following certifications have been awarded to these PCL Antigen Test Kits: CE Certificate, Korea FDA, FIND Listed, UNGM Supplier. Countries includes the EU, 2 countries in the Middle East- Qatar and UAE, India, Russia, 3 countries in Latin America- Guatemala, Ecuador, and Colombia.

The PCL Antigen Detection kit has the CE Certificate meaning that the manufacturer and products have met EU declaration of standards for health, safety, and environmental protection, allowing this product to be sold within the 22 countries in the European Economic Area.

Worldwide, currently there have been over 19.7M people who have been tested positive for COVID-19 but the actual case count is believed to be higher, as a significant number of asymptomatic people may not have been tested. Even more worrying is that most families have had to wait more than 72 hours for their test results to come back from both public and private labs increasing the possibility of spreading the virus.

Rapid Diagnosis Kit is easy when there are no symptoms even after COVID-19 infection, or when ‘positive’ and ‘negative’ are not evident in tests such as RT-PCR. When an infection occurs, an antigen against COVID-19 is formed in the body after some time, so it is a post-test that is essential as a preventive measure.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. Health Canada must approve these COVID-19 test kits before they can be used in Canada. The Company plans to sell these kits in all countries where the kits have been approved for sale.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Primary Logo

The Antigen Rapid Diagnosis Kit developed by PCL is a method of fluorescently measuring the presence of a COVID-19 infection. It is an in-vitro diagnostic medicaldevice to detect the SARS-CoV-2 antigen from a person’s oropharyngeal and nasopharyngeal secretions if the specimen contains antigens to SARS-CoV-2, a colored line appears in the T line area.

View the PCL test by clicking the link PCL COVID-19 ANTIBODY TEST – COV0

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy,” said Marshall Gunter, CEO of Datametrex. “These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

PCL states that the clinical sensitivity (confirmed the actual positive of the approved person) is 100% and the clinical specificity (confirmed the actual negative of the negative person) is 97.78%. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

The following certifications have been awarded to these PCL Antigen Test Kits: CE Certificate, Korea FDA, FIND Listed, UNGM Supplier. Countries includes the EU, 2 countries in the Middle East- Qatar and UAE, India, Russia, 3 countries in Latin America- Guatemala, Ecuador, and Colombia.

The PCL Antigen Detection kit has the CE Certificate meaning that the manufacturer and products have met EU declaration of standards for health, safety, and environmental protection, allowing this product to be sold within the 22 countries in the European Economic Area.

Worldwide, currently there have been over 19.7M people who have been tested positive for COVID-19 but the actual case count is believed to be higher, as a significant number of asymptomatic people may not have been tested. Even more worrying is that most families have had to wait more than 72 hours for their test results to come back from both public and private labs increasing the possibility of spreading the virus.

Rapid Diagnosis Kit is easy when there are no symptoms even after COVID-19 infection, or when ‘positive’ and ‘negative’ are not evident in tests such as RT-PCR. When an infection occurs, an antigen against COVID-19 is formed in the body after some time, so it is a post-test that is essential as a preventive measure.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. Health Canada must approve these COVID-19 test kits before they can be used in Canada. The Company plans to sell these kits in all countries where the kits have been approved for sale.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Primary Logo

Datametrex $DM.ca Commenced Rolling Out COVID-19 Screening Solutions in Anticipation of P.O. From Educational Organizations

Posted by AGORACOM-JC at 9:10 AM on Wednesday, August 5th, 2020
  • Commenced rolling out its screening solutions for health and safety in the education sector in anticipation of Purchase Order from schools and international student recruiting agencies by launching of the new COVID-19 pre-screening and screening tools
  • As the current pandemic continues to impact our world, education is one of the most hit industry
  • With schools plan to reopen in September, Datametrex is offering solutions to educational organizations for the health and safety of students, teachers, and administrative staff

TORONTO, Aug. 05, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) – Through its COVID-19 screening solutions, Datametrex has commenced rolling out its screening solutions for health and safety in the education sector in anticipation of Purchase Order from schools and international student recruiting agencies by launching of the new COVID-19 pre-screening and screening tools.

As the current pandemic continues to impact our world, education is one of the most hit industry. With schools plan to reopen in September, Datametrex is offering solutions to educational organizations for the health and safety of students, teachers, and administrative staff. A recent article by the CBC mentioned that language and private schools are struggling to survive the pandemic because they depend on international students coming into Canada. There are roughly 200 language schools across the country, with 40,000 international students in attendance. With the tools available by Datametrex, these organizations could pre-screen, screen, and report on exposures to decrease the spread and mitigate the risk. (https://www.cbc.ca/news/business/language-schools-covid-foreign-students-1.5668592)

“With schools poised to reopen in Fall, we offer important tool to the education industry. Key is not only opening up the school but also maintaining schools to stay open,” said Marshall Gunter, CEO of Datametrex. “With our pre-screening and screening tools, educational organizations can now provide a safer academic environment to the students and safer workplace to teaching staff with rapid results and trends for COVID-19 in real-time.”

These tools were developed as a direct response to customer needs and the ever-changing physical distancing recommendations, safety guidelines, and workplace flexibility initiatives being observed across North America and around the globe.

About Datametrex
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Datametrex $DM.ca Awarded Contract Extension With #USAirForce

Posted by AGORACOM-JC at 11:32 AM on Friday, July 31st, 2020
  • Successfully awarded a second contract in the United States defense industry, United States Air Force via Wright State Applied Research Corp. on July 29, 2020
  • WSARC is provides contracting, security and research administration services for Wright State Research Institute, the University and the state of Ohio, and will head the U.S. Air Force Academic Partnership and Engagement Experiment (APEX) program

TORONTO, July 31, 2020 – Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G) is pleased to announce that it has been successfully awarded a second contract in the United States defense industry, United States Air Force via Wright State Applied Research Corp. (“WSARC”) on July 29, 2020. WSARC is provides contracting, security and research administration services for Wright State Research Institute, the University and the state of Ohio, and will head the U.S. Air Force Academic Partnership and Engagement Experiment (APEX) program.

“This is a great example of renewable business for Datametrex. Getting a one-year contract extension shows that our technology is valued by the client, and marks progress in our plan to expand our mandate with the organization. Datametrex will continue to solidify our position as a trusted solution provider within the U.S. military departments.” says Marshall Gunter, CEO of the Company.

The contract extension continues with the U.S. Air Force researchers at the Air Force Research Laboratory Airman Systems directorate. The Company is working with researchers within the USAF to land and expand, connecting different groups and finding new stakeholders that can benefit from our A.I. offering. The Air Force Research Laboratory’s Airman Systems Directorate is a vital component of the 711th Human Performance Wing. The directorate is composed of a diverse group of scientists and engineers studying developing technologies specific to the human element of warfighting capability.

The Air Force Research Laboratory (“AFRL”) is leading the discovery, development, and integration of affordable warfighting technologies for the U.S. Air and Space Force. AFRL is a scientific research organization operated by the United States Air Force Materiel Command dedicated to leading the discovery, development, and integrate biological and cognitive technologies to optimize and protect integration of affordable aerospace warfighting technologies, planning and executing the Air Force science and technology program, and providing warfighting capabilities to United States air, space, and cyberspace forces.

For more information on this project or to learn how Datametrex can assist your organization in social media discovery, Fake News Filters and BOT detection, please go to www.nexalogy.com

About Datametrex

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.